New hope for Tough-to-Treat lung cancer patients
NCT ID NCT03611738
Summary
This early-stage study is testing whether combining two existing cancer drugs—ceritinib and docetaxel—can help control advanced lung cancer that has stopped responding to standard chemotherapy. The trial aims to find the safest dose of this combination and see if it can shrink tumors in patients with specific types of non-small cell lung cancer. Participants are adults whose cancer has progressed after one to three prior treatments, including platinum-based chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advent Health Orlando
Orlando, Florida, 32804, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.